Routine viral load monitoring almost halves risk of virologic failure in 18-month Kenyan study
Faldaprevir ups interferon response in HIV/HCV co-infection
Simeprevir pushes HCV cure rate above 75% for HIV/HCV co-infection
Contraceptive injections and HIV infection risk – a public health conundrum
New integrase inhibitor dolutegravir helps treatment-experienced people on failing therapy
Second-line NRTI-sparing regimen proves equally effective for resource-limited settings
Can people with resistant HIV omit NRTIs when switching from a failing regimen?
New pro-drug tenofovir alafenamide appears equally effective but better tolerated
